Zura Bio Limited Class A Ordinary Shares
$4.61
-$0.32 (-6.49%)
$4.58Day Range$4.98
Key Statistics
Market Cap
$472.44M
Shares Outstanding
95.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 21, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$4.94
Day High
$4.98
Day Low
$4.58
Volume
1.27M
VWAP
$4.72
Prev Close
$4.93
Transactions
--
Acc. Volume
--
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283640 employees4225 EXECUTIVE SQUARE, LA JOLLA, CA, 92037858-247-0520IPO Mar 21, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001855644
- Ticker Root
- ZURA
- SIC Code
- 2836
About Zura Bio Limited Class A Ordinary Shares (ZURA) Stock
Zura Bio Limited Class A Ordinary Shares (ZURA) closed the 2026-09-16 session at $4.61, down 6.49% versus the previous close (-0.32). The stock opened at $4.94 and traded between $4.58 and $4.98 during that session. Session trading volume was 1.3M shares. The volume-weighted average price (VWAP) is $4.72.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Zura Bio Limited Class A Ordinary Shares has a market capitalization of $472.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. ZURA is listed on the XNAS exchange. The company employs approximately 40 people. Zura Bio Limited Class A Ordinary Shares is headquartered in LA JOLLA, CA. The recorded listing date is 2023-03-21.
On this page you can find market ZURA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.